Compare EPSN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | CGEN |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 143.1M |
| IPO Year | N/A | 2000 |
| Metric | EPSN | CGEN |
|---|---|---|
| Price | $4.87 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 133.2K | ★ 407.8K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 5.24% | N/A |
| EPS Growth | ★ 11.33 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $45,709,605.00 | $6,903,000.00 |
| Revenue This Year | $41.35 | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | $17.84 | ★ N/A |
| Revenue Growth | ★ 46.76 | N/A |
| 52 Week Low | $4.36 | $1.13 |
| 52 Week High | $8.50 | $2.66 |
| Indicator | EPSN | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 46.87 |
| Support Level | $4.55 | $1.47 |
| Resistance Level | $5.09 | $1.67 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 55.36 | 28.01 |
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.